glp 1 agonist vision loss A potentially blinding condition is a very rare side effect of the GLP-1 receptor semaglutide (Ozempic, Wegovy, Rybelsus), the European Medicines Agency (EMA) concluded. https://www.medpagetoday.com/ophthalmology/generalophthalmology/115938?trw=no A Critical Eye on GLP-1

doi: 10.1038/s41577-020-0402-6 42 ChumakovK.AvidanM

Coordinate timing: allow metabolic parameters to be steady often for months and consider that weight change after bariatric procedures stabilizes 12 to 18 months later

Zembowicz A, Hatchett RJ, Radziszewski W, Gryglewski RJ

Peptides offer targeted intervention addressing specific dark circle mechanisms through collagen synthesis improving skin thickness to obscure vessels, brightening compounds reducing melanin production, circulation enhancement reducing stagnant blood pooling, and anti-inflammatory effects decreasing puffiness and discoloration

A positive recommendation followed by FDA rulemaking would create a 503A path for the seven peptides under review